Cargando…
Impaired Humoral Response in Renal Transplant Recipients to SARS-CoV-2 Vaccination with BNT162b2 (Pfizer-BioNTech)
The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has a major impact on transplant recipients, with mortality rates up to 20%. Therefore, the effect of established messenger RNA (mRNA)-based SARS-CoV-2 vaccines have to be evaluated for solid organ transplant patients (SOT) since they...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8146144/ https://www.ncbi.nlm.nih.gov/pubmed/33923063 http://dx.doi.org/10.3390/v13050756 |
_version_ | 1783697331009355776 |
---|---|
author | Korth, Johannes Jahn, Michael Dorsch, Oliver Anastasiou, Olympia Evdoxia Sorge-Hädicke, Burkhard Eisenberger, Ute Gäckler, Anja Dittmer, Ulf Witzke, Oliver Wilde, Benjamin Dolff, Sebastian Kribben, Andreas |
author_facet | Korth, Johannes Jahn, Michael Dorsch, Oliver Anastasiou, Olympia Evdoxia Sorge-Hädicke, Burkhard Eisenberger, Ute Gäckler, Anja Dittmer, Ulf Witzke, Oliver Wilde, Benjamin Dolff, Sebastian Kribben, Andreas |
author_sort | Korth, Johannes |
collection | PubMed |
description | The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has a major impact on transplant recipients, with mortality rates up to 20%. Therefore, the effect of established messenger RNA (mRNA)-based SARS-CoV-2 vaccines have to be evaluated for solid organ transplant patients (SOT) since they are known to have poor responses after vaccination. We investigated the SARS-CoV-2 immune response via SARS-CoV-2 IgG detection in 23 renal transplant recipients after two doses of the mRNA-based SARS-CoV-2 vaccine BNT162b2 following the standard protocol. The antibody response was evaluated once with an anti-SARS-CoV-2 IgG CLIA 15.8 +/− 3.0 days after the second dose. As a control, SARS-CoV-2 IgG was determined in 23 healthcare workers (HCW) and compared to the patient cohort. Only 5 of 23 (22%) renal transplant recipients were tested positive for SARS-CoV-2 IgG antibodies after the second dose of vaccine. In contrast, all 23 (100%) HCWs were tested positive for antibodies after the second dose. Thus, the humoral response of renal transplant recipients after two doses of the mRNA-based vaccine BNT162b2 (Pfizer-BioNTech, Kronach, Germany) is impaired and significantly lower compared to healthy controls (22% vs. 100%; p = 0.0001). Individual vaccination strategies might be beneficial in these vulnerable patients. |
format | Online Article Text |
id | pubmed-8146144 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-81461442021-05-26 Impaired Humoral Response in Renal Transplant Recipients to SARS-CoV-2 Vaccination with BNT162b2 (Pfizer-BioNTech) Korth, Johannes Jahn, Michael Dorsch, Oliver Anastasiou, Olympia Evdoxia Sorge-Hädicke, Burkhard Eisenberger, Ute Gäckler, Anja Dittmer, Ulf Witzke, Oliver Wilde, Benjamin Dolff, Sebastian Kribben, Andreas Viruses Communication The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has a major impact on transplant recipients, with mortality rates up to 20%. Therefore, the effect of established messenger RNA (mRNA)-based SARS-CoV-2 vaccines have to be evaluated for solid organ transplant patients (SOT) since they are known to have poor responses after vaccination. We investigated the SARS-CoV-2 immune response via SARS-CoV-2 IgG detection in 23 renal transplant recipients after two doses of the mRNA-based SARS-CoV-2 vaccine BNT162b2 following the standard protocol. The antibody response was evaluated once with an anti-SARS-CoV-2 IgG CLIA 15.8 +/− 3.0 days after the second dose. As a control, SARS-CoV-2 IgG was determined in 23 healthcare workers (HCW) and compared to the patient cohort. Only 5 of 23 (22%) renal transplant recipients were tested positive for SARS-CoV-2 IgG antibodies after the second dose of vaccine. In contrast, all 23 (100%) HCWs were tested positive for antibodies after the second dose. Thus, the humoral response of renal transplant recipients after two doses of the mRNA-based vaccine BNT162b2 (Pfizer-BioNTech, Kronach, Germany) is impaired and significantly lower compared to healthy controls (22% vs. 100%; p = 0.0001). Individual vaccination strategies might be beneficial in these vulnerable patients. MDPI 2021-04-25 /pmc/articles/PMC8146144/ /pubmed/33923063 http://dx.doi.org/10.3390/v13050756 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Communication Korth, Johannes Jahn, Michael Dorsch, Oliver Anastasiou, Olympia Evdoxia Sorge-Hädicke, Burkhard Eisenberger, Ute Gäckler, Anja Dittmer, Ulf Witzke, Oliver Wilde, Benjamin Dolff, Sebastian Kribben, Andreas Impaired Humoral Response in Renal Transplant Recipients to SARS-CoV-2 Vaccination with BNT162b2 (Pfizer-BioNTech) |
title | Impaired Humoral Response in Renal Transplant Recipients to SARS-CoV-2 Vaccination with BNT162b2 (Pfizer-BioNTech) |
title_full | Impaired Humoral Response in Renal Transplant Recipients to SARS-CoV-2 Vaccination with BNT162b2 (Pfizer-BioNTech) |
title_fullStr | Impaired Humoral Response in Renal Transplant Recipients to SARS-CoV-2 Vaccination with BNT162b2 (Pfizer-BioNTech) |
title_full_unstemmed | Impaired Humoral Response in Renal Transplant Recipients to SARS-CoV-2 Vaccination with BNT162b2 (Pfizer-BioNTech) |
title_short | Impaired Humoral Response in Renal Transplant Recipients to SARS-CoV-2 Vaccination with BNT162b2 (Pfizer-BioNTech) |
title_sort | impaired humoral response in renal transplant recipients to sars-cov-2 vaccination with bnt162b2 (pfizer-biontech) |
topic | Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8146144/ https://www.ncbi.nlm.nih.gov/pubmed/33923063 http://dx.doi.org/10.3390/v13050756 |
work_keys_str_mv | AT korthjohannes impairedhumoralresponseinrenaltransplantrecipientstosarscov2vaccinationwithbnt162b2pfizerbiontech AT jahnmichael impairedhumoralresponseinrenaltransplantrecipientstosarscov2vaccinationwithbnt162b2pfizerbiontech AT dorscholiver impairedhumoralresponseinrenaltransplantrecipientstosarscov2vaccinationwithbnt162b2pfizerbiontech AT anastasiouolympiaevdoxia impairedhumoralresponseinrenaltransplantrecipientstosarscov2vaccinationwithbnt162b2pfizerbiontech AT sorgehadickeburkhard impairedhumoralresponseinrenaltransplantrecipientstosarscov2vaccinationwithbnt162b2pfizerbiontech AT eisenbergerute impairedhumoralresponseinrenaltransplantrecipientstosarscov2vaccinationwithbnt162b2pfizerbiontech AT gackleranja impairedhumoralresponseinrenaltransplantrecipientstosarscov2vaccinationwithbnt162b2pfizerbiontech AT dittmerulf impairedhumoralresponseinrenaltransplantrecipientstosarscov2vaccinationwithbnt162b2pfizerbiontech AT witzkeoliver impairedhumoralresponseinrenaltransplantrecipientstosarscov2vaccinationwithbnt162b2pfizerbiontech AT wildebenjamin impairedhumoralresponseinrenaltransplantrecipientstosarscov2vaccinationwithbnt162b2pfizerbiontech AT dolffsebastian impairedhumoralresponseinrenaltransplantrecipientstosarscov2vaccinationwithbnt162b2pfizerbiontech AT kribbenandreas impairedhumoralresponseinrenaltransplantrecipientstosarscov2vaccinationwithbnt162b2pfizerbiontech |